ASCO 2025
Professor Bex discusses the phase II NEOAVAX trial that evaluated avelumab/axitinib as neoadjuvant therapy in localized RCC.
Samer Srour, MB, talks about the updated ALLO-316 and its use in targeting CD70 in patients with advanced ccRCC.
Researchers investigated the efficacy of platinum plus 5-FU in the treatment of patients with high-risk penile cancer.
Dr. Attard explores how the study's results compare with prior data in the metastatic castration-resistant setting.
Avelumab plus sacituzumab govitecan may improve PFS in patients with advanced bladder cancer.
At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was superior to SOC.
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
The Two Onc Docs weigh IO for BCG-refractory NMIBC, ctDNA monitoring for patients receiving gem/cis for MIBC, and more.
Dr. Machaalani highlights his study that evaluated the association between circulating KIM-1 and mRCC tumor biology.
Dr. James showcases an MMAI model to identify benefit from 2nd-generation ARPIs in hr/nm PCa patients from STAMPEDE.
Drs. Necchi and Tawagi break down in detail the first results of SURE-02 in patients with muscle-invasive bladder cancer.
Adding niraparib to abiraterone and prednisone prolongs rPFS in patients with mCSPC harboring HRR gene alterations.
Dr. Faltas highlights CLONEVO, a trial using preoperative abemaciclib in cisplatin-ineligible MIBC with ctDNA monitoring.
Dr. Hayne speaks about the ANZUP 101 trial results that evaluated the combination of mitomycin and BCG for NMIBC.
Drs. Ong and Roy detail a multinational real-world analysis of the IRONMAN registry on the significance of PSA>0.2.
Dr. Tagawa explains the rationale for EVOLUTION, a phase II analysis of Lu-PSMA-617 with ipilimumab and nivolumab in mCRPC.
Dr. Tagawa contextualizes a post hoc analysis on clonal hematopoiesis in those who received 177Lu-PSMA-617 or cabazitaxel.
Dr. Tagawa showcases the ProstACT Global trial, a phase III study of 177Lu-rosptamab in patients with mCRPC.
Dr. Tagawa breaks down the VIOLET study, a single-arm phase I/II first-in-human results of terbium-161Tb-PSMA-I&T.
Dr. McGregor shares the opening of the STRIKE trial, which investigates adding tivo to pembro in the mRCC adjuvant setting.
Dr. McGregor opens up about the expansion cohort of the phase 1 ARC-20 study, which looked at casdatifan plus cabozantinib.
Dr. Chahoud talks about the results of the expansion cohort of the phase 1b STELLAR-002 study.
Dr. Ozay discusses her study that compared the efficacy of cabazitaxel with lutetium Lu-177 in patients with mCRPC.
Dr. Haas provides an update on a 5-year follow-up of KEYNOTE-564 and the survival benefits of adjuvant pembrolizumab for RCC.
BCG plus mitomycin may be an alternative treatment for patients with high-risk NMBIC as access to BCG is limited worldwide.
Drs. Galsky and Tawagi discuss the NIAGARA trial on perioperative durvalumab in combination with chemotherapy for MIBC.
Vitaly Margulis, MD, UT Southwestern Medical Center, walks through the ENLIGHTED trial interim analysis.
Drs. Galsky and Tawagi detail the event-free survival subgroup analyses based on disease stage from the CREST study.
Drs. Privé and Tagawa discuss the BULLSEYE trial, an analysis of Lutetium-177-PSMA-617 in oligometastatic HSPC.
Dr. Braun showcases an ongoing phase 1/2 trial of the HPKI inhibitor NDI-101150 in clear cell renal cell carcinoma.
Dr. Braun details an integrative analysis of the Checkmate 9ER trial that highlights both circulating and TME biomarkers.
Dr. Zhang gives an update on the PDIGREE trial, including new information on tolerability and treatment response.
Louise Emmett, MD, discusses the ENZA-p trial which studied enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617.
High KIM-1 may be a biomarker of poor prognosis in RCC and correlates with specific LOF mutations, transcriptions programs.
68Ga-NY104 detected using PET/CT shows better diagnostic efficacy than 18F-FDG PET/CT in patients with mccRCC.
Researchers studied clonal hematopoiesis mutations in patients treated with 177Lu-PSMA-617 or cabazitaxel for prostate cancer
Five-year ARCHES follow-up evaluates the overall surival benefit of enzalutamide + ADT in patients with mHSPC.
Researchers suggest that darolutamide may delay deterioration of quality of life in patients with mHSPC.
Updated phase 3 study assesses long-term outcomes of adjuvant pembrolizumab in patients with ccRCC at risk of recurrence.
Tumor microenvironment and circulating factors studied for potential links to treatment response in aRCC.
Interim SURE-02 study examines sacituzumab govitecan plus pembrolizumab in patients with MIBC unfit for chemotherapy.
Updated CREST trial explores sasanlimab plus BCG in BCG-naive, high-risk NMIBC, with new insights by disease stage and tumor.
ctDNA analysis from the NIAGARA trial offers new insights for patients with MIBC receiving perioperative durvalumab.
Enfortumab + pembrolizumab showed improved responses over chemo in untreated la/mUC, per updated EV-302 results.
Pathologic response and IHC post-treatment influx of CD8+CD39+ TILs are linked with prolonged DFS after neoadjuvant therapy.
Researchers evaluated SBRT plus short-term hormonal therapy in oligometastatic HSPC, examining the tolerability and efficacy.
A novel algorithm identifies patients with high-risk non-metastatic PCa who may benefit from second-generation ARPIs.
Nivolumab + ipilimumab provided a favorable landmark OS in cisplatin-ineligible patients with unresectable or metastatic UC.
The addition of ipi/nivo to LuPSMA improved PSA-PFS over 12 months in patients with mCRPC.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on ARANOTE, Metacure, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on KEYNOTE-564, NEOAVAX, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on CREST, ENLIGHTED, and more.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.